Vertex Pharmaceuticals Incorporated (VRTX) reported second-quarter 2024 adjusted loss per share of $12.83, which was wider than the Zacks Consensus Estimate of a loss of $11.50. In the year-ago quarter, Vertex recorded adjusted earnings of $3.89 per share. The significant loss in the quarter was due to costs related to the $4.9 billion acquisition of Alpine Immune Sciences, which was closed in May. The company reported total revenues of $2.65 billion, comprising cystic fibrosis (CF) product revenues. The fi ...